Table 4.

Final Multivariable Models Showing the Association of Independent Variables on Mortality and on Incident Comorbidity, Among Human Immunodeficiency Virus–Positive Participants Only

Dependent Variable	Outcome Mortality HR (95% CI)	P Value	Outcome Incident Comorbidity OR (95% CI)	P Value
Frailty phenotype
Robust	Ref		ref
Prefrail	1.96 (.71–5.39)	.192	1.08 (.74–1.57)	.678
Frail	3.19 (1.02–9.98)	.047	1.90 (1.06–3.41)	.032
Age (per 10 y)	1.94 (1.23–3.07)	.005	1.53 (1.20–1.96)	.001
Sexual risk group
MSM	…		ref
Heterosexual male	…		.90 (.50–1.63)	.731
Female	…		1.84 (1.08–3.12)	.024
Nonwhite ethnicity	…		1.18 (.62–2.22)	.617
Higher vocational education	…		.91 (.63–1.31)	.608
Smoking status
Never	Ref		ref
Former	1.16 (.35–3.87)	.804	1.04 (.67–1.62)	.847
Current	3.41 (1.19 –9.77)	.022	1.46 (.93–2.27)	.099
Alcohol use
Never	Ref		ref
Former	.27 (.06–1.16)	.078	.74 (.34–1.61)	.451
Current	.20 (.05–.77)	.019	.69 (.35–1.35)	.274
No. of preexisting comorbidities
0	…		ref
1	…		.85 (.57–1.28)	.439
2	…		.87 (.51–1.47)	.596
≥ 3	…		.66 (.34–1.27)	.212
CD4 nadir (per 100 cells/μL higher)	1.51 (1.06–2.14)	.022	…
Duration of zalcitabine use (y)	…		1.35 (1.09–1.67)	.005
Cumulative duration of viral load > 1000 copies/mL	…		1.06 (1.00–1.12)	.046

For further details, see Supplementary Table 3, model 5 and Supplementary Table 4, model 6.

Abbreviations: CI, confidence interval; HR, hazard ratio; MSM, men who have sex with men; OR, odds ratio.